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Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant
polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxel 30mgm
 2 intravenous (i.v.),
weekly, plus estramustine 280mg twice daily for 12 weeks. After 2 weeks rest, patients with a decline or stable PSA were treated
with mitoxantrone 12mgm
 2 i.v. every 3 weeks plus prednisone 5mg twice daily for 12 cycles. Forty patients were assessable for
toxicity after docetaxel/estramustine. Main toxicities were grade 3–4 AST/ALT or bilirubin increase in seven patients (17.5%) and
deep venous thrombosis (DVT) in four patients (10%). Twenty-seven patients received mitoxantrone/prednisone. Main toxicities
included DVT in one patient (3.7%) and congestive heart failure in two patients (7%). Thirty-nine patients were assessable for PSA
response. Twenty-nine patients (72.5%; 95% CI 63–82%) obtained a X50% PSA decline with 15 patients (37.5%; 95% CI 20–50%)
that demonstrated a X90% decrease. Median progression-free and overall survival were respectively 7.0 (95% CI 5.8–8.2 months)
and 19.2 months (95% CI 13.9–24.3 months). In conclusion, although this regimen demonstrated a favourable toxicity profile,
sequential administration of mitoxantrone is not able to improve docetaxel activity in patients with HRPC.
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Prostate cancer is the most common cancer in men and the third
estimated cause of death of cancer in the United States in 2006
(Jemal et al, 2006). Androgen ablation is the standard initial
management for metastatic prostate cancer; however, all patients
develop hormone-refractory disease after a median time of 18–24
months. In such condition, second-line hormonal agents lead to
low response rates and brief disease control and multidisciplinary
treatment includes symptomatic treatments, bisphosphonates,
radiotherapy, radioisotopes and chemotherapy (Pienta and Smith,
2005).
Two randomised phase III trials of mitoxantrone plus cortico-
steroids vs corticosteroids alone (Tannock et al, 1996; Kantoff et al,
1999) demonstrated an improvement in quality of life, pain relief
and PSA response rate in favour of mitoxantrone regimens.
Although this significant palliative activity was not matched with
an improvement in survival, mitoxantrone plus prednisone was
considered the standard chemotherapy regimen for hormone-
refractory prostate cancer (HRPC) for a long time. New
chemotherapy agents such as docetaxel combined with estramus-
tine showed interesting activity in phase II trials. They shared
similar mechanisms of action (microtubule stabilisation and
mitotic process disruption) and showed synergistic activity in
prostate cancer cell lines (Stearns et al, 1985; Kreis et al, 1997).
Phase II studies of single agent docetaxel, given every 3 weeks or as
a weekly schedule, showed a PSA response rate of about 45% and
an interesting objective response rate, particularly for the weekly
regimen (40%) (Picus and Schultz, 1999; Beer et al, 2001).
Combination of docetaxel with estramustine led to a very
promising activity. A PSA response rate between 45 and 68% with
an objective response rate of 20–55% was observed in every 3
weeks docetaxel plus estramustine phase II trials (Petrylak et al,
2000; Savarese et al, 2001; Sitki Copur et al, 2001; Sinibaldi et al,
2002). Moreover, weekly docetaxel plus estramustine produced a
X50% decline in PSA in 76% of patients and an objective response
rate of 58% without grade 4 toxicity (Sitki Copur et al, 2001).
Recently, two randomised phase III trials have demonstrated a
significant improvement in overall survival (OS), pain control,
quality of life and PSA response, for docetaxel-based chemo-
therapy, which has become the standard treatment for metastatic
HRPC (Petrylak et al, 2004; Tannock et al, 2004). However, no
second-line chemotherapy is currently available for HRPC, and
mitoxantrone has demonstrated a PSA response rate of 12–20%
even in taxane-resistant patients showing a noncomplete cross
resistance between docetaxel and mitoxantrone (Michels et al,
2006; Rosenberg et al, 2006). In the attempt to improve treatment
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sactivity, combination of three (Colleoni et al, 1997; Smith et al,
1999; Segawa et al, 2005) or more (Smith et al, 2003) chemotherapy
agents was investigated in phase II studies. These trials reported a
PSA response rate in 58–65% of patients and a measurable disease
response between 32 and 58%, but an incidence of grade 3–4
haematological toxicity in 12–48% of patients. Moreover, febrile
neutropaenia in 15% of patient and one toxic death were reported
in one study (Colleoni et al, 1997). The significant toxicity
observed with polichemotherapy regimens makes the combination
of docetaxel plus estramustine and mitoxantrone probably not
easily feasible, particularly in this often elderly and ‘fragile’
population of patients. At the time of study design, no data
concerning docetaxel efficacy or better schedule of administration
were available. We design this sequential phase II study of 12
weeks docetaxel regimen in accordance to previous findings by
Beer et al (2001) and Sitki Copur et al (2001). Moreover, we
administered sequential mitoxantrone/prednisone in case of
response of stable disease to expose patients, who mostly benefit
from docetaxel chemotherapy, to both agents at therapeutic doses,
avoiding additive toxicity and potentially increasing activity.
MATERIALS AND METHODS
Eligibility criteria
Eligible patients had histologically documented adenocarcinoma of
the prostate and had failed to benefit from androgen ablation and
subsequent antiandrogen withdrawal for their metastatic or locally
advanced disease. All patients met the following criteria: age X18
years; measurable disease progression or PSA serum level
increasing on three consecutive measurements at least 2 weeks
apart; PSA X10ngml
 1; Eastern Cooperative Oncology Group
(ECOG) performance status p2; no prior chemotherapy included
estramustine; discontinued prior antiandrogen treatment by at
least 4 weeks (6 weeks in the case of bicalutamide); adequate bone
marrow function (leucocytes X3500ml
 1, neutrophil count
X1500ml
 1, haemoglobin level X10g per 100ml, platelets
X100000ml
 1); adequate liver function (total serum bilirubin
level o1.5mg per 100ml, AST and ALT o2.5 upper normal limit);
adequate renal function (serum creatinine level o1.5mg per
100ml); and written informed consent. Patients with uncontrolled
metabolic diseases, cardiovascular disease (uncontrolled
arrhythmia, myocardial infarction within 2 years before enrol-
ment, unstable angina, NYHA grade II or greater congestive heart
failure) or active infections were excluded.
Treatment
All eligible patients received docetaxel 30mgm
 2 by 1h intra-
venous (i.v.) infusion on day 1 on a weekly schedule plus
estramustine phosphate 280mg orally two times daily from day 1,
for 12 weeks. After 2 weeks rest from the last docetaxel infusion,
patients who had achieved X50% PSA serum value decline or had
stable disease received mitoxantrone 12mgm
 2 by 1h i.v. infusion
every 3 weeks plus prednisone 5mg orally two times daily,
continuously, up to 12 courses. Each chemotherapy sequence was
discontinued in case of unacceptable toxicities or disease
progression. Chemotherapy was withheld for 1 week in case of
absolute neutrophil count o1000ml
 1 or if an NCI-CTC grade 2
or greater mucositis or gastrointestinal or cutaneous toxicities
occurred. In the absence of recovery from toxicities within 3
weeks, patients discontinued the study. A 25% dose reduction for
neutropaenic fever or any grade 3 toxicity and a 50% dose
reduction for any grade 4 toxicity was recommended (except for
grade 3–4 anaemia, alopecia, nausea and vomiting). Estramustine
was interrupted for any grade 2–3 toxicity and restarted at a 50%
dose reduction after recovery and was definitively stopped in case
of any grade 4 toxicity. The LHRH analogue previously
administered was continued during the study.
Evaluation
Pretreatment evaluations included medical history, physical
examination, complete blood count, serum biochemistry, PSA
levels and pain evaluation according to the visual analogical scale
(VAS). During docetaxel–estramustine treatment, the following
were evaluated every week—physical examination, toxicity (NCI-
CTC) record, blood count and serum biochemistry (creatinine,
total bilirubin, AST, ALT, alkaline phosphatase); every 2 weeks—
serum PSA level; every 3 weeks—blood count, total serum
biochemistry and pain evaluations (VAS). During mitoxantrone–
prednisone therapy, serum PSA level, blood count, total serum
biochemistry and pain control (VAS) were evaluated every 3
weeks. Nuclear ventriculography (multiple-gated acquisition
scanning, MUGASCAN) was performed before mitoxantrone
administration and repeated at the sixth and ninth cycle.
End points and response evaluation
The primary end point of the study was PSA response defined by a
decrease X50% from baseline, maintained for at least 4 weeks, in
accordance with the consensus guidelines of the PSA Working
Group (Bubley et al, 1999). PSA stabilisation was defined by a
decrease o50% or an increase o25% from baseline, maintained
for at least 4 weeks and progressive disease by an increase in serum
PSA X25% from baseline or X50% from nadir, confirmed by two
consecutive measurements at 2 weeks interval. Secondary end
points were objective response rate according to RECIST criteria,
toxicity (NCI-CTC), duration of PSA response, time to PSA
progression, OS and pain control evaluations (VAS).
Statistical analyses
This was a multicentre, prospective, nonrandomised phase II
clinical trial where PSA response was the primary end point.
According to the Simon’s minimax two-stage design with
P0¼50%, P1¼70%, a¼0.10 and b¼0.10, the enrolment of 23
patients was required in the first step of the study. If at least 12
objective responses were observed, a total of 39 assessable patients
were enrolled. Study treatment was considered interesting if at
least 24 out of 39 patients responded. Time to progression and OS
were calculated from the date of first chemotherapy infusion to the
date of progression or death/lost on follow-up, respectively. Time
to progression and OS were analysed according to the Kaplan–
Maier method. Response duration was calculated from the time
of first objective response to the time of disease progression. An
intent to treat analysis was performed.
RESULTS
Characteristics of the patients and treatment
Between September 2002 and July 2005, 40 patients from two
institutions were enrolled. Median age was 72 years (range: 55–
83), 19 patients (47.5%) had an ECOG performance status of 0 and
21 patients (52.5%) had an ECOG performance status of 1, median
serum PSA level was 58ngml
 1 (range: 12–912ngml
 1), bone was
the most frequent metastatic site (68%), 17 patients had a
measurable disease (43%), 13 patients (33%) had undergone
previous prostatectomy and 13 patients (33%) had received
previous radiotherapy for their primary tumour. Eleven patients
(27.5%) had a VAS X1 bone pain (Table 1). In total, 397 courses of
weekly docetaxel plus estramustine and a total of 199 three-weekly
cycles of mitoxantrone plus prednisone were delivered. The
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first part of the treatment and 7 (range: 2–12) for the second.
Toxicity
Docetaxel plus estramustine followed by mitoxantrone plus
prednisone were overall well-tolerated. All patients (40) were
assessable for toxicity after docetaxel/estramustine. Only one
patient developed NCI-CTC grade 2 neutropaenia and anaemia
plus grade 3 thrombocytopaenia and grade 4 stomatitis that
required hospitalisation. Seven patients (17.5%) showed a grade 3
increase of AST/ALT and/or bilirubin serum levels, resolved in
four patients, after treatment delay or dose reductions. Four
patients (10%) developed deep venous thrombosis (DVT) requiring
estramustine discontinuation. Twenty-seven out of 40 patients
received mitoxantrone/prednisone and were assessable for toxicity.
Thirteen patients did not receive this second part of the treatment
due to progressive disease (five patients), severe liver toxicity
unresolved after 3 weeks rest (three patients) or patient’s refusal
to continue (five patients). The main grade 3–4 toxicities
were neutropaenia in two patients (7%) and onycholysis in
three (11%) patients. One patient developed DVT and two patients
(7%) discontinued mitoxantrone due to the onset of congestive
heart failure resolved with medical treatments. No toxic-related
deaths were observed in each sequence of the planned treatment
(Table 2).
Activity
Thirty-nine patients were assessable for PSA response. One out of
40 patients refused study treatment continuation after the onset of
an allergic reaction during docetaxel first administration. Overall,
twenty-nine patients (72.5; 95% CI 63–82%) showed a confirmed
PSA decrease X50% from baseline, with 15 out of 29 patients
(37.5; 95% CI 20–50%) demonstrating a confirmed X90%
decrease in PSA serum levels. Seven (17.5%) patients had a PSA
stabilisation and three patients (7.5%), a PSA progression (Table 3).
Seventeen patients had a measurable disease according to RECIST
criteria. Two patients achieved a complete response (12%), six
patients showed a partial response (35%) with an overall response
rate of 47% and three patients showed a stable disease (17%). After
docetaxel/estramustine, 24 patients with a PSA response and three
patients with a PSA stabilisation received mitoxantrone plus
prednisone. Four patients (10%), showing a X50% PSA decrease
with docetaxel plus estramustine treatment, improved their
response achieving a PSA decrease X90% during mitoxantrone/
prednisone; no patients with PSA stabilisation during docetaxel/
estramustine improved response with the second part of the
treatment. Median duration of PSA response was 8.5 months (95%
Table 1 Patient characteristics
No (%)
No. of patients 40
Age
Median 72
Range 55–83
ECOG performance status
0 19 (47.5)
1 21 (52.5)
Locally advanced disease 3 (8)
Metastatic disease 37 (92)
Sites of disease
Prostate 27 (68)
Bone 27 (68)
Nodes 17 (43)
Liver 3 (8)
No. of involved organs
1 11 (28)
41 29 (73)
Prior treatment
Hormone therapy 40 (100)
Radiotherapy 13 (33)
Prostatectomy 13 (33)
Serum PSA
Median (ngml
 1)5 8
Range 12–912
Gleason score
p7 13 (32.5)
8–10 18 (45)
Not available 9 (22.5)
Pain
VAS scale X1 11 (27.5)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
Table 2 Maximum toxicity per patient
Docetaxel/
estramustine
(40 patients)
Mitoxantrone/
prednisone
(27 patients)
G1–2 G3–4 G1–2 G3–4
Toxicity No. (%) No. (%) No. (%) No. (%)
Neutropaenia 4 (10) 1 (2.5) 9 (33) 2 (7)
Thrombocytopaenia 3 (7.5) 1 (2.5) 3 (11) 0 (0)
Anaemia 36 (90) 1 (2.5) 22 (81) 0 (0)
Nausea 28 (70) 1 (2.5) 5 (18.5) 0 (0)
Vomiting 20 (50) 0 (0) 2 (7) 0 (0)
Asthenia 29 (73) 2 (5) 16 (59) 1 (4)
Anorexia 25 (63) 0 (0) 9 (33) 0 (0)
Diarrhoea 24 (60) 0 (0) 7 (26) 0 (0)
Onycholysis 9 (22.5) 1 (2.5) 8 (29) 3 (11)
Dermatitis 9 (22.5) 1 (2.5) 4 (15) 0 (0)
Sensory neuropathy 8 (20) 0 (0) 0 (0) 0 (0)
Liver toxicity 8 (20) 7 (17.5) 1 (4) 0 (0)
Stomatitis 19 (47.5) 2 (5) 8 (29) 0 (0)
Deep venous thrombosis 0 (0) 4 (10) 0 (0) 1 (4)
Congestive heart failure 0 (0) 0 (0) 0 (0) 2 (7)
Table 3 PSA and objective response (RECIST)
No. (%)
PSA response (39 patients)
PSA decline X90% 15 37.5
95% CI 20–51
PSA decline X50% 29 72.5
95% CI 63–82
PSA stabilisation 7 17.5
PSA progression 3 7.5
Objective response (17 patients)
CR 2 12
PR 6 35
SD 3 17
CR+PR 8 47
95% CI 29–65
PD 6 35
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(95% CI 8–10.8 months) in responder patients who had received
the two chemotherapy sequences. After a median follow-up of 24.2
months, median progression-free survival was 7.0 months (95% CI
5.8–8.2 months) and median OS was 19.2 months (95% CI 13.9–
24.3 months) (Figure 1). Median progression-free survival and
median OS in the 27 patients who had received the two chemo-
therapy sequences were 11.3 (95% CI 6.98–15.63 months) and 26.0
months (95% CI 20.6–31.4 months) respectively. Moreover, the
principal patterns of disease progression, in the 27 patients who
received all the chemotherapy sequence, was biochemical (20
patients, 74%), while skeletal or soft-tissue progression occurred in
a minority of patients (four patients, 15% and two patients, 7%
respectively). Eleven out of 40 patients (27.5%) had a basal VAS
X1 bone pain and among them, median baseline VAS was 4
(range: 1–10). Eight out of 11 patients (73%) experienced pain
relief with the best response at week 4 of docetaxel/estramustine
(median VAS value of 0, range: 0–4). Before receiving mitoxan-
trone/prednisone, 8 out of 27 patients (29.6%) had pain with a
median VAS of 2.5 (range: 1–6). Pain relief was seen in three
patients (37.5%) with best response after 1 cycle of mitoxantrone/
prednisone (median VAS value of 2, range: 1–6).
DISCUSSION
Until few years ago, chemotherapy for HRPC showed modest
activity and no survival benefits and mitoxantrone plus prednisone
was approved only for its palliative activity (Tannock et al, 1996;
Kantoff et al, 1999). New chemotherapy regimens, such as
docetaxel given every 3 weeks (Picus and Schultz, 1999) or as a
weekly schedule (Beer et al, 2001), showed a PSA response rate of
46% (for both schedules) and an objective response rate of 24 and
40% respectively, in phase II studies. Moreover, its combination
with estramustine demonstrated a very promising activity with
manageable toxicity (Petrylak et al, 2000; Savarese et al, 2001; Sitki
Copur et al, 2001; Sinibaldi et al, 2002). In particular, a randomised
phase II trial of every 3 weeks or weekly docetaxel, in combination
with estramustine and prednisone vs mitoxantrone and predni-
sone, reported a PSA response rate of 63%, a time to PSA
progression of 9.3 months and a median survival of 18.4 months
with the weekly schedule, which also presented a good toxicity
profile (Oudard et al, 2005). Recently, two randomised phase III
trials have demonstrated, for the first time, a statistically
significant survival advantage for docetaxel-based regimens in
patients with HRPC. Docetaxel given every 3 weeks plus
prednisone, demonstrated an improvement in survival (median
18.9 vs 16.4 months, P¼0.0009), pain control (RR: 35 vs 22%,
P¼0.01) and PSA response rate (45 vs 32%, Po0.001) when
compared with mitoxantrone and prednisone (Tannock et al,
2004). The second study compared docetaxel and estramustine vs
mitoxantrone and prednisone. A significant advantage was shown
for the docetaxel-containing arm as concerning OS (median 17.5 vs
15.6 months, P¼0.02), time to progression (median 6.3 vs 3.2
months, Po0.001) and PSA response rate (50 vs 27%, Po0.001)
(Petrylak et al, 2004)
22. Polichemotherapy regimens have also been
evaluated in HRPC patients. Combination of three or more agents
yielded a biochemical response rate of 58–65% and an objective
response in 32–58% of patients (Colleoni et al, 1997; Smith et al,
1999, 2003; Segawa et al, 2005). However, such schedules showed
grade 3–4 haematological toxicity ranging from 12 to 48% (Smith
et al, 1999, 2003; Segawa et al, 2005) with febrile neutropaenia in
15% of patients and one toxic death reported in one study
(Colleoni et al, 1997). To increase the activity, but to maintain a
good toxicity profile, in an often elderly and unfit population we
performed the present phase II trial of sequential chemotherapy
with docetaxel plus estramustine, followed by mitoxantrone and
prednisone. In particular, we selected the weekly docetaxel
schedule for its better toxicity profile compared to the every 3
weeks schedule. Moreover, no complete cross resistance between
docetaxel and mitoxantrone has been shown in HRPC and this
observation further supported our sequential design. (Michels
et al, 2006; Rosenberg et al, 2006). Our regimen was feasible with a
favourable toxicity profile. After docetaxel/estramustine, there
were no relevant grade 3–4 haematological toxicities with the
exception of a grade 3 increase in serum levels of GOT, GPT and
bilirubin in seven (17.5%) and DVT in four (10%) patients.
Mitoxantrone/prednisone, after docetaxel/estramustine, was also
well tolerated in docetaxel-pretreated patients. With regard to the
activity, we have observed a confirmed PSA response rate of 72.5%
(95% CI 63–82%) with a median duration of 8.5 months (95% CI
3.85–13.1 months) and an objective response rate of 47%. Median
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Figure 1 Progression-free and overall survival curves.
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and median OS of 19.2 months (95% CI 13.9–24.3 months) are
also interesting (Figure 1). Sequential chemotherapy was, also,
evaluated in a previous phase II study in HRPC. In particular, Font
et al (2005) reported in 30 patients treated with sequential
mitoxantrone plus prednisone followed by every 3 weeks docetaxel
plus estramustine, a PSA response rate of 23% after mitoxantrone/
prednisone with an increase to 63% after docetaxel/estramustine.
The median progression-free survival was 10 months with a
median survival of 18 months and the most frequent toxicity was
grade 3–4 neutropaenia (13% of patients treated with mitoxan-
trone/prednisone and 20% with docetaxel/estramustine). In our
sequential study, mitoxantrone did not contribute to increase
overall schedule activity, but it seemed to be able to control
advanced prostate cancer without relevant toxicity. An adequate
trial incorporating time to progression or time to treatment failure
as primary end point could better evaluate this chemotherapeutic
strategy.
In conclusion, sequential chemotherapy with docetaxel plus
estramustine followed by mitoxantrone plus prednisone is overall
a well-tolerated regimen. However, although sequential use of
mitoxantrone does not seem to improve docetaxel activity, its
potential role as a maintenance therapy could be of interest for
further studies in HRPC.
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